Publications by authors named "A C Vigil"
Objective: To evaluate the clinical usefulness and costs of routine postoperative hematocrit testing after elective general surgery.
Methods: We reviewed charts of all patients who had elective general surgery at New Mexico Veterans Affairs Health Care System, Albuquerque hospital from 2011 through 2014. Demographic data and patient characteristics (eg, comorbidities, smoking/drinking history), estimated blood loss (EBL), pre- and postoperative hematocrit levels, and signs and symptoms of anemia were compared in patients who did or did not receive a blood transfusion within 72 hours of the operation.
We present a case of a 60-year-old male with known seropositive rheumatoid arthritis and cerebral vasculitis who presented to the emergency room with abrupt onset lower back and abdominal pain. The patient developed peritonitis which led to an abdominal laparotomy where jejunal ischemia, necrosis, and perforation were found, requiring bowel resection. On pathology examination, the patient had mesenteric vessel intramural inflammation indicative of vasculitis.
View Article and Find Full Text PDFArticle Synopsis
- * A targeted mass spectrometry technique called multiple reaction monitoring (MRM) has been combined with ultra-high performance liquid chromatography (UPLC) to create an assay that accurately quantifies structural proteins of the new biotherapeutic VSV-GP.
- * The optimized MRM assay allows for simultaneous quantification of multiple targeted proteins while using heavy-labeled reference standards to ensure accurate and precise results, enhancing our understanding of VSV-GP's processing and functionality.
Placentation presents immune conflict between mother and fetus, yet in normal pregnancy maternal immunity against infection is maintained without expense to fetal tolerance. This is believed to result from adaptations at the maternal-fetal interface (MFI) which affect T cell programming, but the identities (i.e.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic castration-resistant prostate cancer is still incurable, despite recent treatments, and tumors show increased glycolysis as they progress.
- The study introduces BKIDC-1553, a new small-molecule compound that inhibits glycolysis specifically in prostate cancer cells without causing severe toxicity, and demonstrates promising results in preclinical models.
- BKIDC-1553 shows effective growth inhibition in various prostate cancer models and has safety and pharmacokinetic properties that suggest it’s ready for clinical trials to treat advanced prostate cancer.